No, there is no approved vaccine for HIV, the virus that causes AIDS. Despite more than 40 years of research and billions of dollars in funding, every vaccine candidate tested in large-scale human trials has failed to provide meaningful protection. HIV remains one of the most difficult targets in vaccine science, though several promising new approaches are now in early testing.
Why HIV Has Been So Hard to Vaccinate Against
HIV is unlike most viruses that vaccines have successfully targeted. The core problem is the virus’s extraordinary genetic diversity. HIV mutates rapidly, producing countless variants even within a single infected person. Most vaccines work by training the immune system to recognize a specific viral shape, but HIV is a constantly moving target.
The only part of HIV exposed on its surface, and therefore the only piece the immune system’s antibodies can latch onto, is a protein called the envelope glycoprotein. This protein is the key HIV uses to enter human immune cells. But it’s heavily coated in sugar molecules that act like a molecular cloak, hiding critical regions from the immune system. The parts of the protein that don’t change much between variants are tucked into recessed crevices, making them especially hard for antibodies to reach.
There’s also a fundamental problem that doesn’t exist for most other vaccines: no one has ever naturally cleared an HIV infection. With diseases like measles or smallpox, vaccine developers can study how the body’s immune system wins the fight and then design a vaccine to trigger that same response. With HIV, there’s no natural blueprint to copy. The virus integrates its genetic material into human DNA within days of infection, establishing a permanent reservoir that the immune system cannot eliminate.
The Closest Anyone Has Come
The most encouraging result in HIV vaccine history came from a trial in Thailand known as RV144, which enrolled more than 16,000 volunteers. The results, published in 2009, showed a 31.2% reduction in HIV infections among vaccinated individuals compared to a placebo group. That was the first time any HIV vaccine candidate showed even modest protection.
A 31% efficacy rate was not considered high enough for licensure, but it proved that a vaccine-induced immune response could offer some degree of protection. Researchers spent years trying to build on that finding.
Those follow-up efforts have not succeeded. The most recent large-scale trial, called Mosaico, tested a vaccine regimen designed to work against multiple HIV subtypes in a diverse global population of over 3,000 participants. The results were definitive: the vaccine provided zero protection. HIV infection rates were 3.63 per 100 person-years in the vaccine group versus 3.35 in the placebo group, translating to an estimated efficacy of negative 0.7%. The vaccine performed no better than a placebo.
Another major trial, PrEPVacc, was stopped in November 2023 after independent monitors determined there was virtually no chance the vaccines being tested would show any benefit. The investigators were blunt: “These vaccines won’t be taken any further.”
The New Strategy: Training the Immune System Step by Step
The failures of traditional approaches have pushed researchers toward a fundamentally different vaccine strategy built around a special class of antibodies called broadly neutralizing antibodies. These antibodies are rare, but they can disable a wide range of HIV variants because they target the small regions of the virus that remain constant even as it mutates.
A small percentage of people living with HIV naturally develop these antibodies after years of infection, but by then the virus is already permanently established. The goal of the new approach is to coax the immune system into producing these antibodies before infection occurs.
This requires a technique called germline targeting. Rather than giving a single vaccine shot, researchers are designing a series of carefully sequenced immunizations. The first shot activates specific precursor immune cells. Subsequent booster shots gradually guide those cells through a maturation process until they can produce broadly neutralizing antibodies. Think of it as training wheels for the immune system, with each dose nudging it closer to the desired response.
One priority target is an antibody called 10E8, which can neutralize an especially broad range of HIV variants. It works by binding to a conserved region on the virus’s surface protein involved in cell entry. The challenge is that this region sits in a recessed crevice, so researchers have engineered synthetic molecules on nanoparticles that mimic the shape of that hidden spot, essentially bringing the target out into the open where the immune system can learn to recognize it. An NIH-led study found this approach successfully activated the right precursor immune cells in animal models.
mRNA Technology Enters the Picture
The success of mRNA vaccines against COVID-19 opened a new toolkit for HIV research. Moderna has a Phase 1 trial underway testing two mRNA-based HIV vaccine candidates. These vaccines use the same delivery platform as the COVID shots but carry instructions for producing HIV-specific proteins designed to kickstart the germline targeting process described above.
The trial is active but no longer recruiting participants, and no results have been posted yet. Phase 1 trials test safety and basic immune responses in small groups, so even positive results would be years away from translating into a product. The NIH’s proposed budget for HIV/AIDS research in fiscal year 2024 was $3.67 billion, a 15% increase over previous funding, with mRNA and self-amplifying RNA vaccine technologies specifically highlighted as priority areas.
How Prevention Works Right Now
While vaccine research continues, HIV prevention has advanced dramatically through other means. Pre-exposure prophylaxis, or PrEP, is now available in several forms. The newest option is an injectable medication given once every six months. In clinical trials, it was 100% effective at preventing HIV infection in women and 96% effective in a predominantly male population over a year of follow-up. Daily oral PrEP pills, available since 2012, are also highly effective when taken consistently.
These numbers set a high bar for any future vaccine. A vaccine with 31% efficacy, like the Thai trial result, would be hard to justify when existing prevention tools are above 95% effective. That said, a vaccine would offer something PrEP cannot: protection that doesn’t depend on ongoing access to medication or adherence to a dosing schedule. For the hundreds of millions of people in regions with limited healthcare infrastructure, a one-time or infrequent vaccination could be transformative.
Where Things Stand
Every large-scale HIV vaccine trial to date has failed, and the two most recent ones produced especially discouraging results. But the scientific approach has fundamentally shifted. Researchers are no longer trying to create a conventional vaccine using older methods. The current generation of candidates uses precision-engineered proteins, nanoparticle delivery systems, and mRNA technology to guide the immune system through a multi-step training process that has never been attempted for any other disease.
Whether this approach will work remains genuinely uncertain. The early-stage trials now underway will take years to produce answers, and success in Phase 1 does not guarantee success in larger trials. As the PrEPVacc investigators noted after their trial’s failure, the world still needs an HIV vaccine as part of its prevention toolkit. The science is more sophisticated than ever, but the virus remains one of the hardest problems in immunology.